参考文献/References:
[1].Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of ameri[J].J Am?Coll?Cardiol, 2017, 68(13):1476-1488.
[2].Mozaffarian D, Benjamin EJ, Go AS, et al. Correction to: heart disease and stroke statistics—2017 update: a report from the american heart association[J]. Circulation, 2017, 129(1):e28-92.
[3].Members WG , Mozaffarian D , Benjamin EJ , et al. Heart disease and stroke statistics-2016 update: a report from the american heart association[J]. Circulation, 2016, 133(4):e38-360.
[4].Almufleh A, Marbach J, Chih S, et al. Ejection fraction improvement and reverse remodeling achieved with sacubitril/valsartan in heart failure with reduced ejection fraction patients[J]. Am J Cardiovasc Dis, 2017, 7(6):108-113.
[5].Beltrán P, Palau P, Domínguez E, et al. Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study[J]. Int J Cardiol, 2018, 252:136-139.
[6].Solomon SD , Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan relative to??a prior decompensation: the PARADIGM-HF trial[J]. JACC Heart Fail, 2016, 4(10):816-822.
[7].McMurray JJ, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure[J]. New Engl J Med, 2014, 371(11):993-1004.
[8].McMurray, John JV. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances[J]. Eur J?Heart?Fail, 2015, 17(3):242-247.
[9].Campbell DJ. Long-term neprilysin inhibition - implications for arnis[J]. Nat Rev Cardiol,2017,14:171-186
[10].Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker[J]. J Am Coll Cardiol, 2016, 68(6):639-653.
[11].Cannon JA, Shen L1, Jhund PS, et?al.PARADIGM-HF Investigators and Committees. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction[J]. Eur J Heart Fail,2017,19: 129-137.
[12].Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers[J]. Am J Hypertension, 2015, 28(3):289-299.
[13].Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of alzheimer disease[J]. Rejuvenation Res, 2010, 13(2-3):195-201.
[14].Bhat SA, Goel R, Shukla S, et al. Angiotensin receptor blockade by inhibiting glial activation promotes hippocampal neurogenesis via activation of Wnt/β-catenin signaling in hypertension[J]. Mol Neurobiol, 2018, 55(6): 5282-5298.
[15].刘滔, 徐俊波, 吴镜. 沙库巴曲缬沙坦治疗心力衰竭的新进展[J]. 心血管病学进展, 2018, 39(3):185-188.
[16].Tanzi RE. The genetics of alzheimer disease[J]. Csh Perspect Med,2012, 2(10): 687-94.
[17].Thorin E. Hypertension and alzheimer’s disease: another brick in the wall of awareness[J]. Hypertension,2015,65: 36-38.
[18].Cannon JA , McMurray J, Quinn TJ. ‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure[J]. Alzheimers Res Ther, 2015, 7(1):22.
[19].Valenti R , Pantoni L, Markus HS. Treatment of vascular risk factors in patients with a diagnosis of alzheimer’s disease: a systematic review[J]. BMC Medicine, 2014, 12(1):160.
[20].Elkahloun AG, Hafko R, Saavedra JM. An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease[J]. Alzheimers Res Ther, 2016, 8:5.
[21].Pandharipande PP, Girard TD, Jackson JC, et?al.BRAIN-ICU study investigators. long-term cognitive impairment after critical illness[J].N Engl J Med,?2013, 369(14): 1306-1316.
[22].Schoenfeld HA, West T, Verghese PB, et al. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey[J]. Toxicol Appl Pharmacol, 2017, 323:53-65.
[23].Tyler JM, Teerlink JR. The safety of sacubitril-valsartan for the treatment of chronic heart failure[J]. Expert Opin Drug Saf, 2017, 16(2):257-263.
[24].Shuko T, Naoyuki S, Ryuichi M. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in alzheimer disease: relevance to pathogenesis and therapy[J]. Front Aging Neurosci, 2014,6:171.
[25].Grodin JL, Hammadah M, Fan Y, et al. Prognostic value of estimating functional capacity using the duke activity status index in stable patients with chronic heart failure[J]. J Card Fail, 2015, 21(1):44-50.
[26].Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor neprilysin inhibition?in heart failure with preserved?ejection fraction: rationale and design of the PARAGON-HF trial[J]. JACC Heart Fail, 2017, 5(7):471.
[27].Langenickel TH,?Tsubouchi C,?Ayalasomayajula S,et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects[J]. Br J Clin Pharmacol,2016,81(5):878-890.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(9):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(9):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(9):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(9):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(9):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]克丽比努尔·吾提库尔,买苏木·买合木提.脑啡肽酶抑制剂在缺血性心脏病中的研究进展[J].心血管病学进展,2015,(5):600.[doi:10.3969/j.issn.1004-3934.2015.05.019]
KELIBINUER·Wutikuer,MAISUMU·Maihemuti.Neprilysin Inhibitors Progress in Ischemic Heart Disease Study[J].Advances in Cardiovascular Diseases,2015,(9):600.[doi:10.3969/j.issn.1004-3934.2015.05.019]
[8]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[9]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(9):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[10]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]